Tarceva Helps Patients With Genetically Distinct Form of Lung Cancer Live Longer
Chicago, June 8, 2010 (ots/PRNewswire) - New data show that first-line treatment with Tarceva(R)(erlotinib) delivered exceptional survival benefits in patients with advanced lung adenocarcinoma (a form of non small cell lung cancer) with epidermal growth factor receptor (EGFR) activating mutations.[1] The phase II data show that Tarceva plus chemotherapy resulted in ...
mehr